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METHODOLOGY Open Access
Detecting eukaryotic microbiota with
single-cell sensitivity in human tissue
Susanne Lager1,2† , Marcus C. de Goffau3†, Ulla Sovio1,2, Sharon J. Peacock3,4,5, Julian Parkhill3,
D. Stephen Charnock-Jones1,2 and Gordon C. S. Smith1,2*
Abstract
Background: Fetal growth restriction, pre-eclampsia, and pre-term birth are major adverse pregnancy outcomes.
These complications are considerable contributors to fetal/maternal morbidity and mortality worldwide. A
significant proportion of these cases are thought to be due to dysfunction of the placenta. However, the
underlying mechanisms of placental dysfunction are unclear. The aim of the present study was to investigate
whether adverse pregnancy outcomes are associated with evidence of placental eukaryotic infection.
Results: We modified the 18S Illumina Amplicon Protocol of the Earth Microbiome Project and made it capable of
detecting just a single spiked-in genome copy of Plasmodium falciparum, Saccharomyces cerevisiae, or Toxoplasma
gondii among more than 70,000 human cells. Using this method, we were unable to detect eukaryotic pathogens
in placental biopsies in instances of adverse pregnancy outcome (n = 199) or in healthy controls (n = 99).
Conclusions: Eukaryotic infection of the placenta is not an underlying cause of the aforementioned pregnancy
complications. Possible clinical applications for this non-targeted, yet extremely sensitive, eukaryotic screening
method are manifest.
Keywords: 18S rRNA gene, Sequencing, Infection, Placenta, Pregnancy complication, Fetal growth restriction,
Pre-eclampsia, Pre-term birth
Background
Fetal growth restriction (FGR), pre-eclampsia, and pre-term
birth are major adverse pregnancy outcomes, and a signifi-
cant proportion of cases are thought to be due to placental
dysfunction. However, the mechanisms underlying this pla-
cental dysfunction remain obscure. Infections during preg-
nancy may result in adverse outcomes. Pregnancy is
associated with increased susceptibility to certain infections,
including candidiasis and Plasmodium falciparum [1–3].
Furthermore, protozoal infections are a significant contrib-
uting factor in stillbirths [4]. Plasmodium falciparum infec-
tion has also been associated with maternal death, reduced
fetal growth, and pre-term births. Generally, pregnancy out-
comes are poorer with increasing placental P. falciparum
infection [4]. As part of a systematic study using
culture-free methods to determine whether these disorders
may be caused by microbial or viral pathogens, we set out
to investigate whether adverse pregnancy outcome was as-
sociated with evidence of placental eukaryotic infection.
One molecular method to detect eukaryotic pathogens
is amplification and sequencing of 18S rRNA genes.
When we addressed this aim, we initially employed the
methodological approach described by the Earth Micro-
biome Project (EMP) [5, 6]. However, the context of
EMP analyses frequently involves niches where the mi-
crobial eukaryotic biomass is abundant compared to
other 18S rRNA signals. Detection of 18S rRNA genes
from potential pathogens in human biopsies is problem-
atic as (i) even low levels of signal would be highly rele-
vant and (ii) the 18S rRNA gene is also present in the
human genome (unlike the bacterial 16S rRNA gene).
Consequently, development and application of
PCR-based diagnostic methods for human eukaryotic
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infections has been slow [7, 8], resulting in a dearth of
well-conducted 18S rRNA gene sequencing studies, in
contrast to the numerous 16S rRNA gene sequencing
studies. Shotgun-metagenomics analyses similarly suffer
from the fact that close to 100% of the DNA obtained
from human biopsies is human, greatly reducing the de-
tection sensitivity of (rare) eukaryotic pathogens. Hence,
we first set out to develop a modified approach for the
18S Illumina Amplicon Protocol of the EMP which would
maximize the signal from potential eukaryotic pathogens
over the human host. Second, we employed the optimized
protocol in order to determine whether pregnancies com-
plicated by FGR, pre-eclampsia, or pre-term birth are as-
sociated with eukaryotic infection of the placenta.
Methods
Ethics
The Pregnancy Outcome Prediction study (POPs) was ap-
proved by the Cambridgeshire 2 Research Ethics Committee
(reference number 07/H0308/163). All study participants
gave informed written consent. The design and conduct of
the study are described in detail elsewhere [9]. The charac-
teristics of the eligible women and those who participated in
POPs have also previously been described [10].
Patient selection
From the POPs cohort [9, 11], placentas from 60
healthy, term deliveries (≥ 37 weeks’ gestation) were se-
lected for a pilot study to investigate the influence of
mode of delivery and sample collection time on
eukaryotic microbes detected (clinical characteristics are
presented in Additional file 1: Table S1).
To study associations between placental eukaryotic in-
fection and pregnancy complications, cases of FGR (less
than third percentile based on customized birth weight
accounting for gestational age, fetal sex, maternal
weight/height, ethnicity, parity, and smoking [12] (n =
50) or pre-eclampsia according to the 2013 ACOG
Guidelines (The American Congress of Obstetricians
and Gynecologists [13]; n = 49)) were selected (Add-
itional file 1: Table S2). All pre-eclampsia cases displayed
severe features of pre-eclampsia; specifically, they had ei-
ther severe hypertension (systolic blood pressure ≥
160 mmHg, diastolic blood pressure ≥ 110 mmHg) or
evidence of hepatic, renal, hematologic, cerebral, or pul-
monary complications [13]. Cases were matched
one-to-one with healthy controls (n = 99). Cases and
controls were all term deliveries (≥ 37 weeks’ gestation).
The matching criteria were the following: mode of deliv-
ery (absolute match) and as close as possible for mater-
nal BMI, maternal age, gestational age, sample collection
time (i.e., the interval between birth and collection of
the placenta), maternal smoking, and fetal sex. In
addition, placentas from 100 pre-term deliveries
(< 37 weeks’ gestation) were selected. Clinical character-
istics are presented in Additional file 1: Table S2.
Placenta collection
Placental villous tissue was collected after delivery as
previously described in detail [9]. Briefly, after removal
of the basal plate, villous tissue was obtained from four
different lobules of the placenta. The selected tissue
samples had no visible damage, hematomas, or infarc-
tions. Maternal blood was removed by washing the tis-
sue samples in ice-cold phosphate-buffered saline.
Tissue was rapidly frozen in liquid nitrogen and stored
at − 80 °C until further processing. For the DNA isola-
tion, approximately 25 mg of villous tissue was cut from
the stored tissue. In the pilot study, tissue from the four
biopsy collection points were studied combined (n = 60),
as well as separate biopsies from four of these women
(n = 44; 11 biopsies each from four placentas). In the
pregnancy complication study, tissue from all four bi-
opsy collection points were combined (n = 298). To re-
duce the risk of environmental contamination of the
samples, the processing was performed in a Class 2 bio-
logical safety cabinet with single-use sterile forceps and
scalpels. Each matched case-control pair was processed
in parallel together on the same day. For all subsequent
steps, the case-control pairs were processed in parallel
using the same lot of reagents.
DNA isolation
DNA was isolated from placental tissue with the Fast
DNA Spin kit (MP Biomedical, Santa Ana, CA, USA). Tis-
sue was homogenized by bead-beating (2 cycles of 40 s,
speed 6.5 on a FastPrep-24; MP Biomedical). Samples
were placed on ice for 5 min between each bead-beating
cycle. To protect the samples from possible environmental
contamination, the DNA isolation was also performed in a
Class 2 biological safety cabinet. Cabinet and pipettes were
cleaned with DNA AWAY Surface Decontaminant (Fisher
Scientific, Loughborough, UK). Gloves changed between
handling each sample. All plastics used for the DNA ex-
traction, as well as subsequent steps, not supplied in the
kits were nuclease-free: PCR clean 2.0 and 1.5 ml DNA
LoBind Tubes (Eppendorf, Hamburg, Germany) and
nuclease-free filter tips (TipONE sterile filter tips, STAR-
LAB (UK), Ltd., Milton Keynes, UK). Extraction blanks
were performed for each box of DNA isolation kit used.
These DNA extraction blanks, or negative controls, did
not contain any added biological material, solely the re-
agents of the DNA isolation kit subjected to the complete
DNA extraction procedure (bead-beating, matrix binding,
spin filtering, washing, and elution of nucleic acids). The
DNA extraction blanks were subjected to the entire ana-
lysis protocol alongside the placental samples: DNA isola-
tion, 18S rRNA gene PCR amplification, sequencing, and
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data analysis. Matched case-control pairs were processed
together on the same day, using the same DNA isolation
kit batch. DNA concentrations were determined by Nano-
drop Lite (ThermoFisher Scientific, Waltham, MA, USA).
Positive control experiments
Isolated DNA from Plasmodium falciparum (kind gift
from Dr. Julian Rayner, Wellcome Trust Sanger Insti-
tute), Toxoplasma gondii (cat# 50174D; ATCC, Manas-
sas, VA, USA), and Saccharomyces cerevisiae (strain
Y7092; kind gift from Dr. Nianshu Zhang, University of
Cambridge) was added in a randomized order (1, 10,
100, 1000, or 10,000 genome copies) per 500 ng of DNA
isolated from human placenta (equivalent to > 70,000
cells). A total of approximately 500 ng DNA was used
for each of the detection limit assays (18S rRNA gene
sequencing and HiSeq X Ten sequencing).
EMP protocol PCR amplification of 18S rRNA gene
The V9 region of the 18S rRNA gene was amplified with
primers: Forward-1391 5′- AAT GAT ACG GCG ACC
ACC GAG ATC TAC ACT ATC GCC GTT CGG TAC
ACA CCG CCC GTC-3′ and Reverse-EukBr 5′- CAA
GCA GAA GAC GGC ATA CGA GAT nnn nnn nnn
nnn AGT CAG TCA GCA TGA TCC TTC TGC AGG
TTC ACC TAC-3′ [the n string represents a unique
12-mer barcode]. In order to reduce amplification of hu-
man 18S rRNA gene, a blocking primer was included
during the PCR reaction (5′-GCC CGT CGC TAC TAC
CGA TTG GII III TTA GTG AGG CCC T-3SpC3; each
I indicates deoxyInosine, and “SpC3” a C3 Spacer phos-
phoramidite at the 3′-end of the primer which prevents
primer extension). The 18S rRNA gene amplifications
were carried out with 5 Prime HotMasterMix (5 Prime
GmbH, Hamburg, Germany). The Primer design and the
PCR amplification protocol have previously been de-
scribed by the EMP (http://www.earthmicrobiome.org/)
and used in publications [14–16].
Q-PCR optimization of 18S rRNA gene PCR conditions
Known amounts of DNA from S. cerevisiae or P. falcip-
arum were added to human DNA isolated from pla-
centa. Quantification of 18S PCR amplicons was carried
out in triplicate on a 7900HT Fast Real-Time PCR Sys-
tem (Applied Biosystems, Foster City, CA, USA). The
18S rRNA amplicons were detected with human forward
5′-CTA CTA CCG ATT GGA TGG TT-3′ (final conc.
0.5 μM), human reverse 5′-TCA AGT TCG ACC GTC
TTC-3′ (final conc. 0.5 μM), human probe [6FAM]-TAG
TGA GGC CCT CGG ATC GGC-[MGB/NFQ] (final
conc. 0.25 μM), S. cerevisiae forward 5′-GTC GCT AGT
ACC GAT TGA A-3′ (final conc. 0.1 μM), S. cerevisiae
reverse 5′-TCC AAA TTC TCC GCT CTG-3′ (final
conc. 0.1 μM), and S. cerevisiae probe [6FAM]-AGC
AGA TCC TGA GGC CTC ACT AAG C-[MGB/NFQ]
(final conc. 0.1 μM). The PCR cycling conditions to de-
tect human 18S PCR amplicons were an initial step of
95 °C for 10 min followed by 30 cycles of 95 °C (15 s)
and 63 °C (1 min). The PCR to detect S. cerevisiae 18S
PCR amplicons was run with an initial step of 95 °C for
10 min followed by 30 cycles of 95 °C (15 s) and 60 °C
(1 min). TaqMan Universal master mix (Life Technolo-
gies, Carlsbad, CA, USA) was used in the amplifications.
Optimized dual-index approach for 18S rRNA gene
amplification and sequencing
The 18S rRNA gene was amplified in triplicate (pilot ex-
periment) or quadruplicate (pregnancy complication co-
hort) reactions with 180 ng DNA/reaction. The final
concentration of the forward and reverse primers was
0.2 μM and of the blocking primer 3.2 μM. All primers
were purchased from Eurofins Genomics (Ebersberg,
Germany). Working aliquots of the primers were pre-
pared in a Class 2 biological safety cabinet (cleaned with
DNA AWAY Surface Decontaminant), in PCR clean
nuclease-free DNA LoBind Tubes (Eppendorf ) with
nuclease-free filter tips (TipONE sterile filter tips,
STARLAB) and Tris-EDTA buffer (Sigma-Aldrich Com-
pany Ltd., Gillingham, UK). In the single-index ap-
proach, a barcode was present only on the reverse
primer. In the dual-index approach, a barcode was in-
cluded in the forward primer as well: Barcoded
forward-1391: 5′-AAT GAT ACG GCG ACC ACC GAG
ATC TAC CAn nnn nnn nnn nnT ATC GCC GTT CGG
TAC ACA CCG CCC GTC-3′ [the n string represents
unique 12-mer barcode]. 18S rRNA gene amplifications
were carried out with 5 Prime HotMasterMix (5 Prime
GmbH) and UltraPure DNase/RNase-Free Water
(Thermo Fisher Scientific) in 0.2 ml PCR strips (STAR-
LAB). PCR amplification was carried out on a SureCy-
cler 8800 Thermal Cycler (Agilent Technologies,
Stockport, UK). PCR amplification comprised an initial
step of 94 °C for 3 min followed by 30 cycles of 94 °C
(45 s), 65 °C (15 s), 57 °C (30 s), and 72 °C (90 s). After
completion of cycling, the reactions were incubated for
10 min at 72 °C. After completion of the PCR, replicates
of each sample were pooled, with DNA precipitated in a
mixture of 1 M NaCl and 99.5% ethanol (Sigma-Aldrich)
overnight. Samples were spun at 14,000g for 20 min and
the pellet washed in 70% ethanol and spun at 14,000g
for 12 min. The pellet was air-dried in a Class 2 bio-
logical safety cabinet before being resuspended in
Tris-EDTA buffer (Sigma-Aldrich) overnight. DNA con-
centrations were determined by Qubit fluorometry (Invi-
trogen, Carlsbad, CA, USA). Equimolar pools of the
PCR amplicons were run on 1% agarose/TBE gels, DNA
was visualized with ethidium bromide, and excised
bands were cleaned up with a Wizard SV Gel and PCR
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Clean-Up System (Promega UK, Southampton, UK).
The equimolar pools were sequenced on the Illumina
MiSeq platform using paired-end 250 cycle MiSeq Re-
agent Kit V2 (Illumina, San Diego, CA, USA).
18S MiSeq data analysis
Quality control and merging of paired reads was performed
with PEAR (v0.9.5) using its default settings [17] except for
a minimum overlap size of 40 base pairs. Due to the limited
size of the V9 region, there is a full overlap of the entire se-
quenced region. Merged reads were subsequently analyzed
using the QIIME assign_taxonomy.py script (v1.9.1) using
the mothur assignment method option and the 18S Sil-
va_119_rep_set97_18S.fna reference library [18–20]. The
first MiSeq run, which used only a single-index on the re-
verse primer, revealed that P. falciparum and T. gondii
reads, likely originating from the positive control samples,
were detected in placental samples that should not have
any of these reads. To verify the origins of these incorrectly
assigned reads and the likely mechanism of the incorrect
read assignment, a dual-index sequencing approach was in-
stead implemented on these same samples. This repeat ana-
lysis using a dual index was also analyzed by the Illumina
MiSeq platform as if there was still only a single index on
the reverse primer, using the same CSV input file, to see if
the previous results could be replicated. The index on the
forward primer could then subsequently be utilized to see
where these errant reads originated from, due to the limited
size of the V9 region. In this analysis, matching or
non-matching forward barcodes were searched for within
the 250 nucleotide long reverse reads by searching nucleo-
tide positions 110–155 for the presence of the correct for-
ward barcode using the Excel function IF (ISNUMBER
(SEARCH(“barcode”,“read”)),true,false). Both “false” and
“true” reads were separated and put into individual reverse
read fastq files, matched with their respective forward reads
using the makepairs function of git.io/pairfq_lite and were
subsequently analyzed as described above with PEAR and
QIIME. Merged “false” reads which were identified as either
P. falciparum or T. gondii were double-checked to verify
that the index on their forward primer indeed corre-
sponded to one of the forward indexes used for the positive
controls by again searching nucleotide positions 110–155
of the corresponding (unmerged) reverse read for a barcode
used in one of the positive controls. A dual-index approach
was used for all subsequent MiSeq runs providing the Illu-
mina MiSeq platform with a dual-index CSV file.
HiSeq X Ten data analysis
The same positive control samples used for the MiSeq
18S experiments were also analyzed by whole genome
sequencing using the Illumina HiSeq X Ten. For the li-
brary preparation of the HiSeq X Ten platform sample,
DNA levels were first quantified with a Biotium
Accuclear Ultra High Sensitivity dsDNA Quantitative kit
(Cambridge Bioscience, Bar Hill, Cambridge, UK) using
the Mosquito LV liquid platform (TTP Labtech, Mel-
bourn, Cambridgeshire, UK), Bravo WS (Agilent, Santa
Clara, CA, USA), and BMG FLUOstar Omega plate
reader (BMG Labtech, Aylesbury, Buckinghamshire, UK)
and cherrypicked to 200 ng/120 μl using a Tecan liquid
handling platform (Tecan, Männedorf, Switzerland).
Cherrypicked plates were sheared to 450 bp using a Cov-
aris LE220 instrument (Covaris, Woburn, Massachusetts,
USA). Post-sheared samples were purified using Agen-
court AMPure XP SPRI beads (Beckman Coulter, Brea,
CA, USA) on an Agilent Bravo WS (Agilent). Library
construction (ER, A-tailing and ligation) was carried out
using a “NEB Ultra II custom kit” (NEB, Ipswich, Massa-
chusetts, USA) on an Agilent Bravo automation system
(Agilent). The PCR was carried out with KapaHiFi Hot
start mix (Kapa Biosystems, Wilmington, Massachusetts,
USA) and IDT 96 iPCR tag barcodes (Integrated DNA
Technologies, Coralville, Iowa, USA) using the Agilent
Bravo WS automation system (Agilent). The PCR ampli-
fication profile was an initial step of 95 °C for 5 min
followed by 5 cycles of an initial step of 98 °C (30 s),
30 s at 65 °C, and 1 min at 72 °C. After completion of
cycling, the reactions were incubated for 10 min at 72 °
C. DNA from the post-PCR plate was purified using
Agencourt AMPure XP SPRI beads (Beckman Coulter)
on a Beckman BioMek NX96 liquid handling platform
(Beckman Coulter). Libraries were again quantified with
the Biotium Accuclear Ultra High Sensitivity dsDNA
Quantitative kit (Cambridge Bioscience) using the Mos-
quito LV liquid platform (TTP Labtech), Bravo WS (Agi-
lent), and BMG FLUOstar Omega plate reader (BMG
Labtech). Libraries were pooled in equimolar amounts
using a Beckman BioMek NX-8 liquid handling platform
(Beckman Coulter) and were normalized to 2.8 nM for
cluster generation on a c-BOT and loading onto the Illu-
mina HiSeq X Ten platform (Illumina). Sequencing of
the samples (150 bp, paired end) resulted in 402 million
pairs of reads on average per sample (range 388–420
million, 3.2 billion total paired reads in lane). On aver-
age, 97.6% of all reads (range 97–98%) were initially
mapped to the host sequence (human reference genome)
with Bowtie 2 (v2.2.3, default settings) and were subse-
quently removed. A custom Kraken (v0.10.6) [21] refer-
ence database was built in order to detect any potential
non-human eukaryotic signal using metagm_build_kra-
ken_db and -max_db_size 30. This custom Kraken refer-
ence database included both the default bacterial and
viral libraries, and an accessions.txt file was supplied (via
-ids_file) containing a diverse array of organisms chosen
from all sequenced forms of eukaryotic life (see Add-
itional file 1: Table S3 for accession numbers). This wide
array was chosen to both detect potentially relevant
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unknown organisms and to identify human reads which
had not been mapped to the human reference genome.
Kraken was run using the metagm_run_kraken option.
Apparent non-human eukaryotic signals were found in
every placental sample at a similar percentage, and on
further analysis, these turned out to be human reads that
were not removed when mapped against the human ref-
erence genome; this was apparent as Kraken mapped
most of these reads to the various Animalia (Chordata)
species (see Additional file 1: Table S3). Additional
in-depth assembly-based taxonomic analyses would have
been performed if an unexpected relevant non-human
eukaryotic signal was detected, but none were found.
Statistics and positive control data normalization
Differences between groups when optimizing the 18S rRNA
PCR conditions were evaluated by repeated measures
ANOVA. P values less than 0.05 were considered statistically
significant. Statistical calculations were performed in Graph-
Pad Prism 7 (GraphPad Software, Inc., La Jolla, CA, USA).
The signals of the various eukaryotic signatures in the
positive control samples were normalized based upon
the remaining proportion of human 18S reads. This
normalization utilizes the fact that all samples contain
the same amount of human DNA (same weight of tissue
per sample). However, quantifying reads relative to the
human signal required correction for the size of any
non-human signal. This is required as large non-human
signals significantly lower the percentage of human reads
detected. To illustrate, if a sample only contains human
DNA, approximately 99.9% of all reads will be taxonom-
ically assigned as being from a human after sequencing.
If a sample also contains, for example, a large S. cerevi-
siae signal, accounting for ~ 50% of all reads, this will
depress all other smaller positive control signals by a
factor of ~ 2. To account for signal depression of and
due to the three eukaryotic spiked species in the various
positive control samples, each positive control sample
was first normalized to an arbitrary number of 100,000
reads in order to compare them in subsequent steps.
Secondly, a correction factor (CF) is calculated based
upon the total eukaryotic signal strength in a positive
control or in other words on the depression of the per-
centage of human reads (which represent a fixed
eukaryotic signal strength in each sample) by other
eukaryotic signals as follows:
Correction factor ¼ 1þ 99:9−Human %ð Þð Þ
Human %ð Þ
The 99.9% refers to the percentage of reads that would
be taxonomically assigned as being from a human in a
placental sample without any microbial signature. The
normalized number of reads for each eukaryote-detected
signal is multiplied by the correction factor (step 2) to
calculate a value for the signal strength of each
eukaryotic signal (P. falciparum, S. cerevisiae, and T.
gondii) that can be directly compared with the corre-
sponding eukaryotic signals from the other positive con-
trols. For example, if S. cerevisiae accounts for 50% of all
reads, P. falciparum accounts for 20% of all the reads,
and T. gondii accounts for 5% of all reads, and where
the remainder is human, the correction factor would be
~ 4, and hence, the adjusted output would be approxi-
mately 50,000 × 4 = 200,000 for S. cerevisiae, 20,000 × 4
= 80,000 for P. falciparum, 5000 × 4 = 20,000 for T. gon-
dii, and 100,000 for Homo sapiens.
Results
Optimization of 18S PCR conditions
To increase the sensitivity of the EMP protocol in hu-
man tissue samples, mammal blocking primer concen-
trations and annealing temperature were first optimized
to maximize the ratio of non-human to human 18S
reads. The optimization was performed using a range of
P. falciparum or S. cerevisiae DNA concentrations (≤
1%) added to human placental DNA samples. When
comparing the samples with the lowest proportion of S.
cerevisiae, doubling the blocking primer amount
(3.2 μM) while keeping the EMP protocol’s annealing
temperature (65 °C) resulted in optimal inhibition of hu-
man 18S rRNA gene amplification (Fig. 1 and Add-
itional file 1: Figure S1).
Single-index 18S rRNA sequencing
Next, we studied three groups: (1) 44 placental samples
obtained from four placentas delivered following a nor-
mal pregnancy (11 biopsies per placenta), (2) positive
controls (placental samples with added P. falciparum, T.
gondii, and S. cerevisiae DNA; n = 6), and (3) negative
controls (blanks; Fig. 2a–c). Each of the samples was
identified using single-index barcoded 18S rRNA ampli-
cons, as per the EMP protocol, and all samples were
pooled and sequenced in a single lane. We detected the
pathogen signals in all of the positive controls. However,
additionally, P. falciparum reads were detected in 27 out
of the 49 other samples, including several strong signals
(< 0.1% of reads) equivalent to 100-genome copies
(Fig. 2a). Similarly, T. gondii reads were found in low
amounts (~ 0.001% of reads) in 27 out of 49 samples
(Fig. 2b). Finally, Saccharomyces reads were found to
represent around 0.01% of all reads in 48 out of 49 sam-
ples, including all negative controls (Fig. 2c). It was ap-
parent that we were obtaining false-positive results as (i)
none of the four women providing healthy placental
samples was documented as having any infection, (ii)
multiple biopsies from the same woman were not con-
sistently positive or negative for the given pathogen, (iii)
Lager et al. Microbiome  (2018) 6:151 Page 5 of 11
the negative controls also demonstrated the presence of
pathogen DNA, and (iv) we could not replicate the P.
falciparum or T. gondii signals in a second sequencing
run (Additional file 1: Figure S2). Notably, the second
sequencing run did not include any positive control
samples.
Dual-index 18S rRNA sequencing
We hypothesized that the unexpected P. falciparum or
T. gondii reads from the healthy placentas could be ex-
plained by primer cross-contamination and or
mis-assignment, which leads to reads from one sample
being incorrectly assigned to a different sample. Hence,
we repeated the analysis of the same DNA samples but
employed dual-index primer sequencing (i.e., a unique
index at both ends of the amplicon). In contrast to the
single-index primer approach, neither P. falciparum nor
T. gondii reads were detected in placental samples ex-
cept in the positive controls (Fig. 2d, e). All P. falcip-
arum and T. gondii reads in placental samples for the
single-index run originated from positive controls, due
to index misattribution. In contrast, Saccharomyces
reads were still detected in placental samples and nega-
tive controls (Fig. 2f and Additional file 1: Figure S3).
Sensitivity of 18S rRNA and HiSeq X Ten sequencing
We then assessed the sensitivity of the optimized
dual-index method by analyzing the signals from the
positive controls to which 1, 10, 100, 1000, or 10,000
genome copies of P. falciparum, T. gondii, and S. cerevi-
siae had been added (Fig. 3). After normalizing for the
total eukaryotic signal strength per positive control, this
experiment demonstrated a near-perfect linear
correlation between the number of genome copies added
and the signal obtained for all three species (Fig. 3b).
Moreover, with our approach, this correlation held to a
single genome copy for all three eukaryotic species. For
comparison, we also sequenced the same positive con-
trol samples using the Illumina HiSeq X Ten, aiming for
30-fold coverage of the human genome from the placenta.
Each sample was run on a single lane on the HiSeq X
Ten, resulting in approximately 200 million reads per
sample. The detection limit for P. falciparum and T. gon-
dii was ~ 100 added genome copies (Fig. 3c, represented
by 10 and 827 reads respectively) and was higher for S.
cerevisiae at more than 1000 genome copies.
Placental infection and pregnancy complications
Having optimized a sensitive method for the detection
of 18S rRNA genes from eukaryotic microbes in human
tissue, we then analyzed placental samples from (i) 50
cases of FGR and 50 matched controls, (ii) 49 cases of
severe pre-eclampsia and 49 matched controls, and (iii)
100 cases of preterm delivery. Using the MiSeq
dual-index 18S rRNA gene detection approach, none of
the 298 samples demonstrated read counts indicative of
even one genome copy for a potential eukaryotic patho-
gen. We estimated the upper bounds of the ability of 0/
50 and 0/100 to rule out an association between
eukaryotic infection and the respective outcomes using
the binomial confidence interval. These were 0.0 to 7.1%
and 0.0 to 3.6% of cases, respectively. Saccharomyces
reads were the most commonly detected non-human
eukaryotic reads. However, no sample had more than 15
Saccharomyces reads (Fig. 4), compared with the 163
Fig. 1 Optimization of blocking primer annealing temperature and concentration. The EMP protocol utilizes a mammal blocking primer annealing
temperature of 65 °C and blocking primer concentration of 1.6 μM. a Different blocking primer annealing temperatures were tested for the 18S rRNA
gene amplification. In all reactions, 1.6 μM blocking primer was used. The effect of increasing annealing temperature was determined by quantifying
the yield of product by Q-PCR. A higher Ct indicates more effective blocking of amplification of the human 18S rRNA gene. An annealing temperature
of 61 °C resulted in a significantly higher Ct than at 67 °C or 68 °C (repeated measures ANOVA followed by Tukey’s multiple comparisons test). Data
presented as mean + SEM, n = 3; different letters above bars indicate P < 0.05. b Comparison of blocking primer concentration and annealing
temperature (65 °C) with the original sample of S. cerevisiae of 0.0001%. Data presented as mean + SEM, n = 4. Different letters above the bars indicate
P < 0.05 (repeated measures ANOVA followed by Tukey’s multiple comparisons test)
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Fig. 2 Detection of positive controls with single-index primers and dual-index primers. Detection of a P. falciparum, b T. gondii, and c
Saccharomyces (cerevisiae) in healthy placental samples and positive controls with single-index primers. The same samples were re-analyzed with
dual-index primers for detection of d P. falciparum, e T. gondii, and f Saccharomyces (cerevisiae). Graphs illustrate kit blanks (left; n = 5), healthy
placental samples (middle; n = 44 placental biopsies from four women), and positive controls (right [0 to 10,000 added genome copies ordered
from left to right]; n = 6). With a dual-index sequencing approach, the P. falciparum and T. gondii signals disappear from all the healthy placental
samples (n = 44) and the 0 genome copy control. Signal remains in the positive control samples (right side of graphs; n = 5). The high proportion
of S. cerevisiae reads in blanks (f) was due to an overall low number of total reads in the blanks using dual-index primers. The absolute number of
Saccharomyces 18S reads with the dual-index primers is presented in Additional file 1: Figure S3
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reads observed when a control sample was spiked with a
single genome copy of Saccharomyces.
Discussion
In conducting this study, we identified a number of im-
portant lessons for other researchers searching for evi-
dence of eukaryotic infections. First, the detection of
non-human signal needs to be optimized for extremely
low signals. Second, we found that 18S rRNA gene amp-
lification is much more sensitive (and cost-effective)
than deep sequencing. Third, we found that it is critical
to employ unique indexes on the forward and reverse
primers. The initial unexpected detection of P. falcip-
arum and T. gondii signals in healthy placental samples
turned out to be a sequencing artifact that was solved by
switching from a single-index to a dual-index sequen-
cing approach. Hence, the EMP-based, single-indexing
approach is not suitable for pathogen identification in
human samples as the presence of a single strongly posi-
tive sample in an 18S sequencing run will result in false
positivity of this same signal in multiple other samples.
However, our modified protocol allows detection of
DNA from eukaryotic microbes present in very low
amounts in multiple human biopsies multiplexed in a
single sequencing lane. The false-positive P. falciparum
and T. gondii signals were likely due to barcode
cross-contamination of the primers. This is in line with
previous reports [22], further highlighting the import-
ance of dual-index sequencing approach.
Common approaches for the diagnosis of fungal diseases
are PCR-based amplification, either pan-fungal or species
specific, or antibody-based detection [23]. The detection
limit of PCR-based techniques is generally between 5 and
10 genomic copies for a similar amount of tissue [24], but a
single genome copy sensitivity can be obtained using elec-
trochemically labeled DNA probes or with immunoassays
[25, 26]. The loop-mediated isothermal amplification tech-
nique (LAMP) has similarly achieved a single genome copy
sensitivity of Toxoplasma gondii which is an improvement
over a PCR-based assay [27]. Plasmodium qPCR detecting
high-copy telomere-associated repetitive elements has also
achieved single genome copy sensitivity [28]. Each of these
methods utilizes genus-specific primers whereas our modi-
fied protocol is generally applicable and does not require
any prior knowledge. It is able to detect these various eu-
karyotes at a sensitivity of 1 genomic copy in multiple hu-
man biopsies (dominated by human DNA) in a single
sequencing lane.
Regarding the Saccharomyces reads (and other
minor signals detected in these 18S runs), further
consideration indicates that these were likely to be
the result of reagent contamination by eukaryotic
DNA of environmental origin. It is well recognized
that bacterial DNA of environmental origin is a com-
mon contaminant of laboratory kits. Amplification of
Fig. 3 Sensitivity of 18S rRNA gene sequencing and HiSeq X Ten sequencing. Genome-copy detection limit determination of P. falciparum, T. gondii, and S.
cerevisiae in positive control samples using a dual-index sequencing approach. a Representation of the percentage of 18S reads per eukaryotic positive
control signal as measured. b Normalized representation of the absolute comparative strength of each eukaryotic signal after accounting for a different
total eukaryotic signal strength in each of the positive control samples using 18S amplification. A value of 100,000 is representative of the human signal
strength in each sample; P. falciparum, T. gondii, and S. cerevisiae signal strength values were calculated based upon the total remaining percentage of
human reads in each positive control. c HiSeq X Ten genome-copy detection limit determination of P. falciparum, T. gondii, and S. cerevisiae
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these bacterial contaminants is a hazard in 16S or
metagenomics analyses, especially in samples of low
(microbial) biomass [29, 30]. Given that the sapro-
phytic Saccharomyces genus is ubiquitous in nature
and because Saccharomyces reads were also found
in the negative controls, we hypothesized that
Saccharomyces DNA was present in low amounts in
the laboratory reagents employed [7]. A single
Saccharomyces cerevisiae genome contains 100–200
copies of the 18S rRNA gene [31]. This probably ex-
plains why we were able to detect a single genome
copy with our improved 18S rRNA gene MiSeq
method, more readily than the other positive control
species. Detection of fungal signals well below the
100 reads threshold with this method suggests that
the sequenced DNA is derived from low-level envir-
onmental contamination rather than a true placental
signal. The artificial nature of the signal is supported
by the batch effect observed when comparing these
putative contaminant signals in DNA extractions
using different reagent boxes (Fig. 4). Consistent
with this interpretation, the sample with the highest
number of Saccharomyces reads (69) was a negative
control. Therefore, the data do not support the hy-
pothesis that placental eukaryotic infection is in-
volved in the etiology of placental dysfunction or
that there is any form of eukaryotic microbiota in
the healthy placenta. However, the findings do indi-
cate that 18S rRNA analysis is also prone to detect-
ing contaminants in laboratory kits.
Fig. 4 Detection of fungal reads in placental tissue in pregnancy complications with dual-index primers. a Pre-eclampsia and matched controls (n= 98), b
fetal growth restriction (FGR) and matched controls (n= 100), and c pre-term deliveries (n= 100). The Y-axis represents the number of reads assigned to
being of possible fungal origin (turquoise) and which were assigned to the Saccharomyces genus (yellow if different from the total number of fungal
reads). None of the signals detected reached the 0.1% detection limit or a minimum of 100 fungal reads. The DNA isolations were performed using a
single lot of DNA isolation kits but four different boxes. Matched cases and controls were processed in parallel on the same day, using the same box of
laboratory reagents, and sequenced together in the same pool of 18S rRNA amplicons. Most pre-eclampsia matched cases and controls were sequenced
together in one pool; therefore, the higher number of fungal reads detected may be related to differences in sequencing runs
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The positive control experiments show a need for hav-
ing an internal positive control signal within each sample
and for subsequent total signal strength normalization. In
the case of the placental samples, signal strength
normalization appears to be largely a moot point, but in
other types of samples (with real signals), it is important
to ascertain the actual number of cells of a microorganism
within a sample (tissue) and not the relative abundance as
compared to other microorganisms for purposes of bio-
logical relevance. In the case of 18S rRNA gene studies of
human tissue, the human signal provides a control signal
to allow quantification. This allows one to compare the
relative strengths of the other signals found within these
samples. The actual number of microorganisms that are
present in the sample can then be estimated by compari-
son with positive controls, i.e., non-infected samples
spiked with a known number of genome copies of the
given organism. The use of a positive control may be par-
ticularly important in non-tissue samples, as there is no
equivalent to human 18S and the addition of a positive
control to all samples would facilitate quantification of the
relative eukaryotic signal strengths.
Sequencing of the 18S rRNA gene allows for identifica-
tion of eukaryotic organisms, such as fungi and protozoa,
present within a given sample. Variable region 9 (which
has been amplified in this study using the EMP primers)
has previously been shown to be one of the better regions
to sequence for the identification of eukaryotic diversity
[32]. However, other regions of the 18S rRNA gene or as-
sociated areas may also be utilized to identify microbial
DNA. As example of such other approaches are primers
directed towards internal transcribed spacer (ITS) region.
Targeted sequencing of the ITS region has previously been
shown suitable for identification of fungal species [33–35].
In this study, we further demonstrate that FGR,
pre-eclampsia, and pre-term birth were not associated
with placental eukaryotic infections. No non-human 18S
rRNA signals were detected in any of the placental sam-
ples that even came close to the 18S rRNA stipulated
0.1% detection limit (~ 100 reads). The sample size
allowed us to rule out this being a factor in more than
7% of cases of FGR or pre-eclampsia or 3.6% of cases of
preterm birth. Hence, these data do not support the hy-
pothesis that placental eukaryotic infection may be in-
volved in the etiology of placental dysfunction in the
samples studied. It remains a possibility that this could
be a rare cause of such complications; that it could be a
more common cause in other settings, or that a
eukaryotic pathogen eluded detection by methods
employed in this study.
Conclusions
The critical importance of utilizing optimized protocols
and a dual-index sequencing approach when analyzing
samples with a low eukaryotic microbe biomass has been
illustrated in this study. We also demonstrate that placen-
tal infections with eukaryotic microbes/pathogens are un-
likely as a (common) underlying cause of the pregnancy
complications FGR, pre-eclampsia, or pre-term birth.
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